Beam Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

Beam Therapeutics

24/02/2023 17:02

* Beam Therapeutics Inc  BEAM.OQ   BEAM.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
27 (estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 75.1% decrease in revenue to $12.734 million from $51.07
million a year ago, according to the mean estimate from 12
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Beam Therapeutics
Inc is
for a loss of $1.33 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Beam
Therapeutics
Inc is $70.5​, above​ its last closing price of $40.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.31       -1.31      -1.56     Missed  -18.8
 Jun. 30 2022  -1.10       -1.08      -1.02     Beat    5.4
 Mar. 31 2022  -1.42       -1.32      -1.01     Beat    23.5​
 Dec. 31 2021  -1.03       -1.03      -0.95     Beat    7.6
 ​​Sep.        -0.81       -0.74      -0.42     Beat    43
 30 2021                                                
 Jun. 30 2021  -0.62       -0.65      -1.23     Missed  -90.3​
 Mar. 31 2021  -0.75       -0.74      -3.34     Missed  -352.1
 Dec. 31 2020  -0.71       -0.67      -1.69     Missed  -151.7
 This summary was machine generated February 24 at 17:02 GMT. 
All figures in US dollars  unless otherwise stated